Har haft oturen att hamna med nagelsvamp, haft på en nagel sedan fem år, testat allt, alla dyra medel, medicinska nagellack mm. Fick nog o ringde och krävde läkemedel av husläkaren, hon vägrade (tydligen dåligt för levern), istället rekommenderade hon Terclara, köpte men var jävligt förbannad.
August 29, 2025 at 4:12 PM
Har haft oturen att hamna med nagelsvamp, haft på en nagel sedan fem år, testat allt, alla dyra medel, medicinska nagellack mm. Fick nog o ringde och krävde läkemedel av husläkaren, hon vägrade (tydligen dåligt för levern), istället rekommenderade hon Terclara, köpte men var jävligt förbannad.
Moberg Pharma Partners with Karo Healthcare for European Launch of MOB-015/Terclara#Sweden#Stockholm#Moberg_Pharma#Terclara#Karo_Healthcare
Moberg Pharma Partners with Karo Healthcare for European Launch of MOB-015/Terclara
Moberg Pharma and Karo Healthcare have signed an exclusive agreement for the launch of MOB-015/Terclara in Europe, tapping into 19 markets.
third-news.com
November 5, 2025 at 8:19 AM
Moberg Pharma Partners with Karo Healthcare for European Launch of MOB-015/Terclara#Sweden#Stockholm#Moberg_Pharma#Terclara#Karo_Healthcare
Moberg Pharma's Phase 3 Study in North America Ends Without Primary Endpoint Success#Sweden#Stockholm#Moberg_Pharma#MOB-015#Terclara
Moberg Pharma's Phase 3 Study in North America Ends Without Primary Endpoint Success
Moberg Pharma's Phase 3 study for MOB-015 in North America has not met its primary endpoint, leading the company to refocus efforts in the EU market.
third-news.com
December 10, 2024 at 8:26 PM
Moberg Pharma's Phase 3 Study in North America Ends Without Primary Endpoint Success#Sweden#Stockholm#Moberg_Pharma#MOB-015#Terclara
Moberg Pharma and Karo Healthcare Forge Exclusive Licensing Deal for Terclara Across Europe#Sweden#Stockholm#Moberg_Pharma#Terclara#Karo_Healthcare
Moberg Pharma and Karo Healthcare Forge Exclusive Licensing Deal for Terclara Across Europe
Moberg Pharma has secured an exclusive license with Karo Healthcare to commercialize MOB-015, Terclara in 19 major European markets. This collaboration enhances growth opportunities on a large scale.
third-news.com
November 5, 2025 at 8:15 AM
Moberg Pharma and Karo Healthcare Forge Exclusive Licensing Deal for Terclara Across Europe#Sweden#Stockholm#Moberg_Pharma#Terclara#Karo_Healthcare
Moberg Pharma's Terclara Launch in Norway: A New Era for Nail Fungus Treatment#Norway#Oslo#Moberg_Pharma#Terclara#Allderma
Moberg Pharma's Terclara Launch in Norway: A New Era for Nail Fungus Treatment
Moberg Pharma AB and Allderma have commenced the launch of Terclara® (MOB-015) in Norway, aiming to replicate its Swedish success in the treatment of nail fungus.
third-news.com
February 3, 2025 at 7:32 AM
Moberg Pharma's Terclara Launch in Norway: A New Era for Nail Fungus Treatment#Norway#Oslo#Moberg_Pharma#Terclara#Allderma
Alla går väl runt med nagelsvamp som inte försvinner… Krävs recept för Terclara? Måste du byta skor och skaffa helt nya strumpor samtidigt? Hur lång tid innan effekt?
August 29, 2025 at 4:31 PM
Alla går väl runt med nagelsvamp som inte försvinner… Krävs recept för Terclara? Måste du byta skor och skaffa helt nya strumpor samtidigt? Hur lång tid innan effekt?
Thoughts on this? >> Bayer exits Europe pact with Moberg for nail fungus drug
after Phase 3 fail: Moberg Pharma’s Terclara has flunked a late-stage test evaluating less… >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #pharma #pharmaceutical #biotech #healthcare
after Phase 3 fail: Moberg Pharma’s Terclara has flunked a late-stage test evaluating less… >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #pharma #pharmaceutical #biotech #healthcare
Bayer exits Europe pact with Moberg for nail fungus drug
after Phase 3 fail
Moberg Pharma’s Terclara has flunked a late-stage test evaluating less frequent maintenance dosing for fungal nail infection, prompting Bayer to pull out of planned launch activities in Europe and ending their partnership. The Swedish drugmaker ...
dlvr.it
December 11, 2024 at 1:27 PM
Thoughts on this? >> Bayer exits Europe pact with Moberg for nail fungus drug
after Phase 3 fail: Moberg Pharma’s Terclara has flunked a late-stage test evaluating less… >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #pharma #pharmaceutical #biotech #healthcare
after Phase 3 fail: Moberg Pharma’s Terclara has flunked a late-stage test evaluating less… >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #pharma #pharmaceutical #biotech #healthcare